87 related articles for article (PubMed ID: 1963019)
1. A new model to assess the haemorrhagic potential of various heparin preparations.
Berstad A; Bang CJ; Talstad I
Acta Chir Scand Suppl; 1990; 556():62-7. PubMed ID: 1963019
[TBL] [Abstract][Full Text] [Related]
2. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
3. Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model.
Bang CJ; Talstad I; Berstad A
Eur J Surg Suppl; 1994; (571):23-9. PubMed ID: 7519085
[No Abstract] [Full Text] [Related]
4. Gastric mucosal bleeding after unfractionated and low molecular weight heparin in rats.
Bang CJ; Berstad A; Talstad I
Scand J Gastroenterol; 1990 Apr; 25(4):379-82. PubMed ID: 2159654
[TBL] [Abstract][Full Text] [Related]
5. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats.
Bang CJ; Berstad A; Talstad I
Haemostasis; 1991; 21(1):30-6. PubMed ID: 1650745
[TBL] [Abstract][Full Text] [Related]
6. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
7. Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans.
Bang CJ; Riedel B; Talstad I; Berstad A
Scand J Gastroenterol; 1992 Nov; 27(11):924-8. PubMed ID: 1333639
[TBL] [Abstract][Full Text] [Related]
8. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB
Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271
[TBL] [Abstract][Full Text] [Related]
10. Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin.
Holst J; Lindblad B; Matthíasson SE; Stjernquist U; Ezban M; Ostergaard PB; Hedner U
Thromb Haemost; 1996 Apr; 75(4):585-9. PubMed ID: 8743183
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
Barrowcliffe TW; Thomas DP
Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study of the action of preparations of high- and low-molecular weight heparin on hemostatic indices in vitro and in their intravenous administration to animals].
Kudriashov BA; Pastorova VE; Liapina LA; Kondashevskaia MV; Azieva LD; Sukhanov IuS; Fedeniuk PV; Vasiukov SE; Cherstvova LG
Eksp Klin Farmakol; 1992; 55(1):35-8. PubMed ID: 1339042
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
14. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
15. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
16. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
19. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin.
Matthíasson SE; Lindblad B; Stjernquist U; Bergqvist D
Haemostasis; 1995; 25(5):203-11. PubMed ID: 7489958
[TBL] [Abstract][Full Text] [Related]
20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
